Patents by Inventor Andrew A. Protter

Andrew A. Protter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Breast Cancer
    Publication number: 20210069154
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 11, 2021
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of Breast Cancer
    Publication number: 20190262315
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 29, 2019
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 10111861
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 30, 2018
    Assignees: Medivation Prostate Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of Breast Cancer
    Publication number: 20170087132
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 9517229
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 13, 2016
    Assignees: MEDIVATION PROSTATE THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Pyrido[4,3-b]indoles containing rigid moieties
    Patent number: 9458155
    Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: October 4, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC
    Inventors: David T. Hung, Andrew A. Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES
    Publication number: 20150051218
    Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Inventors: David T. HUNG, Andrew A. PROTTER, Rajendra Parasmal JAIN, Sarvajit CHAKRAVARTY
  • TREATMENT OF BREAST CANCER
    Publication number: 20140296312
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 2, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Tetracyclic compounds
    Patent number: 8338408
    Abstract: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: December 25, 2012
    Assignee: Medivation Technologies, Inc.
    Inventors: David T. Hung, Andrew A. Protter, Rajendra P. Jain, Sundeep Dugar, Sarvajit Chakravarty, Sergey O. Bachurin, Anatoly K. Ustinov, Bogdan K. Beznosko, Nadezhda Sergeevna Beznosko, legal representative, Elena F. Shevtsova, Vladimir V. Grigoriev
  • Tetracyclic compounds
    Publication number: 20090239854
    Abstract: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: October 27, 2008
    Publication date: September 24, 2009
    Inventors: David T. HUNG, Andrew A. PROTTER, Rajendra P. JAIN, Sundeep DUGAR, Sarvajit CHAKRAVARTY, Sergey O. BACHURIN, Anatoly K. USTINOV, Bogdan K. BEZNOSKO, Elena F. SHEVTSOVA, Vladimir V. GRIGORIEV, Nadezhda Sergeevna Beznosko
  • Glycosylated Probnp
    Publication number: 20080312152
    Abstract: The present invention is directed to glycosylated proBNP and pharmaceutical compositions thereof. The present invention also relates to novel assays for measuring the total natriuretic activity that is present in a clinical blood sample.
    Type: Application
    Filed: October 16, 2006
    Publication date: December 18, 2008
    Inventors: N. Stephen Pollitt, Rodney A. Jue, Andrew A. Protter, Jessica O"Rear, Andrew Guzzetta, Ute Schellenberger
  • Oxidized Human Bnp
    Publication number: 20080227713
    Abstract: The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP).
    Type: Application
    Filed: October 3, 2006
    Publication date: September 18, 2008
    Inventor: Andrew A. Protter
  • Methods of promoting osteogenesis
    Patent number: 7268139
    Abstract: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: September 11, 2007
    Assignee: Scios, Inc.
    Inventors: Andrew A. Protter, David Y. Liu, Patrick O'Connor
  • Treatment of obesity and associated conditions with TGF-beta inhibitors
    Publication number: 20040192583
    Abstract: The invention concerns the treatment obesity and associated conditions with TGF-&bgr; inhibitors. More specifically, the invention concerns the use of TGF-&bgr; inhibitors in the treatment of obesity, type 2 diabetes, and pathologic conditions associated with obesity or type 2 diabetes.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 30, 2004
    Inventors: Satyanarayana Medicherla, Andrew A. Protter, George F. Schreiner
  • Methods for treating diabetes
    Publication number: 20040171659
    Abstract: The invention is directed to methods of treating diabetes by administering p38 mitogen activated protein kinase inhibitors. The invention is also directed to methods of decreasing blood glucose level in diabetes patients by administering p38 mitogen activated protein kinase inhibitors.
    Type: Application
    Filed: December 5, 2003
    Publication date: September 2, 2004
    Inventors: Satyanarayana Medicherla, Andrew A. Protter, George F. Schreiner
  • Methods of promoting osteogenesis
    Publication number: 20040162289
    Abstract: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.
    Type: Application
    Filed: August 29, 2003
    Publication date: August 19, 2004
    Inventors: Andrew A. Protter, David Y. Liu
  • Methods for improvement of lung function using TGF-beta inhibitors
    Publication number: 20040146509
    Abstract: The invention concerns methods for improvement of lung function by administering non-peptide small molecule inhibitors of TGF-&bgr; specifically binding to the type I TGF-&bgr; receptor (TGF&bgr;-R1). Preferably, the inhibitors are quinazoline derivatives.
    Type: Application
    Filed: July 23, 2003
    Publication date: July 29, 2004
    Inventors: Zhihe Li, David Y. Liu, Jing Ying Ma, Andrew A. Protter, George F. Schreiner, Thomas-Toan Tran
  • Treatment of pain by inhibition of p38 MAP kinase
    Publication number: 20040122008
    Abstract: The present invention relates to methods for the prevention or treatment of pain by the inhibition of p38 MAP kinase.
    Type: Application
    Filed: September 5, 2003
    Publication date: June 24, 2004
    Inventors: Andrew A. Protter, Camilla Svensson, Tony Yaksh, Barbara Cordell, Sundeep Dugar
  • Treatment of fibroproliferative disorders using TGF-beta inhibitors
    Publication number: 20040038856
    Abstract: The invention concerns methods of treating fibroproliferative disorders associated with TGF-&bgr; signaling, by administering non-peptide small molecule inhibitors of TGF-&bgr; specifically binding to the type I TGF-&bgr; receptor (TGF&bgr;-R1). Preferably, the inhibitors are quinazoline derivatives. The invention also concerns methods for reversing the effect of TGF-&bgr;-mediated cell activation on the expression of a gene associated with fibrosis, comprising contacting a cell or tissue in which the expression of such gene is altered as a result of TGF-&bgr;-mediated cell activation, with a non-peptide small molecule inhibitor of TGF-&bgr;, specifically binding a TGF&bgr;-R1 receptor kinase present in the cell or tissue.
    Type: Application
    Filed: May 16, 2003
    Publication date: February 26, 2004
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, Linda S. Higgins, Ann M. Kapoun, David Y. Liu, Andrew A. Protter, George F. Schreiner, Thomas-Toan Tran
  • Method to treat cystic fibrosis
    Publication number: 20040009990
    Abstract: The invention is directed to methods to treat cystic fibrosis by administering certain imidazole derivatives.
    Type: Application
    Filed: November 8, 2002
    Publication date: January 15, 2004
    Inventors: Linda S. Higgins, David Y. Liu, Andrew A. Protter